AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
This forum identified key actions that can support access to and the appropriate management of treatments for rare diseases within the U.S. health care system.
AMCP webinar that addressed what is currently being seen in the industry and how to effectively support and continue this early, meaningful, and effective exchange of information for pre-approval products.
AMCP urges justices to affirm federal ERISA law to ensure managed care pharmacy practices continue helping patients access medicines at affordable costs.
